Technology | April 16, 2009

iCAD’s Breast MRI-Guided Planning Software Gets 510(k) Clearance

April 16, 2009 – iCAD Inc. today announced it has received 510(k) clearance for PrecisionPoint, the company’s interventional planning solution for breast MRI that can make biopsies easier and faster. PrecisionPoint will be offered as an integrated module within the company’s CADvue breast MRI image review software.

"We continue to improve upon our software offerings to provide clinicians increasingly accurate tools to aid in the detection of breast cancer. Our new PrecisionPoint software enables the user to pinpoint exactly where the biopsy is needed without the need to manually calculate the location and depth of the lesion,” said Rick Ortega, director of MRI programs at iCAD. “Faster and more reliable biopsies could help reduce the need for repeat exams and aid in quicker clinical decision making and treatment for patients."

In addition to the inclusion of PrecisionPoint, iCAD has made a number of other functional and interface improvements to the latest release of its CADvue software. CADvue is a complete MRI image review, analysis and BI-RADS compatible reporting solution that generates contrast enhancement curves, dynamic 3D images and quantification of key lesion parameters. CADvue’s automation of critical manual steps reduces the time required to generate curves and streamlines radiologists’ workflow and diagnosis. The latest CADvue software release includes:
- A compare function that enables radiologists to easily view multiple studies of the same patient;
- Enhancement of MIPs/3D renderings; and
- The addition of CADvue Lite, which gives the user the ability to export CADvue images onto a CD with a DICOM viewer to support improved communication between physicians.

“The addition of PrecisionPoint, coupled with the new features and product enhancements within CADvue, gives clinicians a complete set of tools to improve the review and analysis of breast MRI studies, as well as interventional planning,” said Ortega.

For more information: www.icadmed.com

Related Content

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).

Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).

News | Breast Imaging | March 18, 2021
March 18, 2021 — 
Stefan Vilsmeier Brainlab announced the acquisition of Mint Medical GmbH, a Heidelberg-based company that develops image reading and reporting software for clinical routine and research

Stefan Vilsmeier, President and CEO, Brainlab

News | Treatment Planning | March 10, 2021
March 10, 2021 — Brainlab announced the acquisition of Mint Medic...
Breast cancer is the most common fatal cancer in women. Early detection increases a woman's chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue.
News | MRI Breast | March 09, 2021
March 9, 2021 — Breast cancer is the most common fatal cancer in women.
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy.  The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | March 05, 2021 | By Melinda Taschetta-Millane
The decision to offer...
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...